637039-01-1Relevant articles and documents
5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY
-
, (2021/05/21)
The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
Spirocyclic derivatives
-
, (2016/04/09)
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.
NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES
-
Page/Page column 36-37, (2010/02/06)
The invention relates to novel 2,5-disubstituted pyrimidine derivatives, which stimulate the soluble guanylate cyclase, method for production and use thereof for the production of medicaments, in particular medicaments for the treatment of central nervous system diseases.
PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS
-
Page column 51, (2010/02/06)
The invention relates to the phenylaminopyrimidines of formula (I), wherein A, D, R1, R2, R3 and R4 are defined as in the description. The invention also relates to methods for producing said phenylaminopyrimidines and to their use for producing drugs for the treatment and/or the prophylaxis of diseases, especially cardiovascular diseases.